Skip to contentS
Sarepta Therapeutics, Inc.
S
SRPTSarepta Therapeutics, Inc. Q1 2020 · 10-Q
Revenue$100.45M$100.45M+15.4% vs Q1 2019 Net Income-$17.49M-$17.49MN/M vs Q1 2019 EPS Diluted-$0.23-$0.23N/M vs Q1 2019 Operating Income-$118,026,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sarepta Therapeutics, Inc. · CIK 873303 · Engraved from SEC EDGAR
Free Cash Flowderived$618,670,000N/M Margins · derivedOperating margin-117.5%−29.7 pt vs Q1 2019
Net margin-17.4%+70.7 pt vs Q1 2019
ended Mar 31, 2020 · filed May 6, 2020 · 36 d after period end